Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Fanny Gallix"'
Autor:
Loraine Jarrosson, Clélia Costechareyre, Fanny Gallix, Séverine Ciré, Fabien Gay, Olivier Imbaud, Romain Teinturier, Elisabetta Marangoni, Karine Aguéra, Céline Delloye-Bourgeois, Valérie Castellani
Publikováno v:
iScience, Vol 24, Iss 12, Pp 103423- (2021)
Summary: Lack of preclinical patient-derived xenograft cancer models in which to conduct large-scale molecular studies seriously impairs the development of effective personalized therapies. We report here an in vivo concept consisting of implanting h
Externí odkaz:
https://doaj.org/article/e65639efd1b04677a4ab64cc3627fbe5
Autor:
Jonathan Blachier, Aurore Cleret, Nathalie Guerin, Clara Gil, Jean-Marc Fanjat, Florian Tavernier, Laura Vidault, Fanny Gallix, Nicolas Rama, Rodrigue Rossignol, Diana Piedrahita, Aurély Andrivon, Marie Châlons-Cottavoz, Karine Aguera, Fabien Gay, Françoise Horand, Bastien Laperrousaz
Publikováno v:
Experimental Cell Research. 426:113568
Autor:
Loraine Jarrosson, Clélia Costechareyre, Fanny Gallix, Séverine Ciré, Fabien Gay, Olivier Imbaud, Elisabetta Marangoni, Karine Aguéra, Céline Delloye-Bourgeois, Valérie Castellani
Lack of preclinical patient-derived xenograft (PDX) cancer models in which to conduct large scale molecular studies seriously impairs the development of effective personalized therapies. We report here on an in vivo concept consisting of implanting h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e06dfedaadb2f856ecd9a194a9eeaea0
https://hal.archives-ouvertes.fr/hal-03402513
https://hal.archives-ouvertes.fr/hal-03402513
Autor:
Karine Sénéchal, Sylvie Maubant, Marie Leblanc, Séverine Ciré, Fanny Gallix, Aurély Andrivon, Olivier Duchamp, Fabrice Viviani, Françoise Horand, Alexander Scheer, Vanessa BOURGEAUX
Publikováno v:
Cancer Research. 79:2258-2258
Background : Anti-PD-1 immunotherapy, although efficient in several cancer indications; has shown some limitations due to the appearance of resistance mechanisms. More specifically, the overexpression of A2A receptor (adenosine receptor) on the surfa
Autor:
Karine Aguera, Fanny Gallix, Fabien Gay, Karine Senechal, Severine Cire, Françoise Horand, Alexander Scheer, Vanessa Bourgeaux
Publikováno v:
Cancer Research. 78:5827-5827
L-asparaginase (ASNase), an enzyme currently used in combination with chemotherapy for Acute Lymphoblastic Leukemia (ALL) treatment, hydrolyzes L-asparagine (Asn) - a non-essential amino acid - into aspartic acid (Asp) and ammonia, leading to Asn rem
Autor:
Fabien Gay, Karine Aguera, Karine Senechal, Julie Bes, Anne-Marie Chevrier, Fanny Gallix, Christine Guicher, Philip Lorenzi, Vanessa Bourgeaux, Willy Berlier, Françoise Horand, Yann Godfrin
Publikováno v:
Cancer Research. 76:4812-4812
Based on the asparaginase paradigm, several arginine-catabolizing enzymes have been developed for the treatment of arginine-dependent cancers (Wheatley, 2004). The arginine deiminase (ADI) enzyme catalyzes the hydrolysis of arginine (Arg) (Sugimura,
Autor:
Karine Aguera, Anne-Marie Chevrier, Alexandra Traverse-Glehen, Yann Godfrin, Willy Berlier, Fanny Gallix
Publikováno v:
Cancer Research. 75:5369-5369
L-asparaginase (L-ASPA) is included in current chemotherapy regimen for the treatment of acute lymphoblastic leukemia (ALL). The sensitivity of ALL to L-ASPA has been linked to the incapacity of leukemic cells to produce their own asparagine, since t
Autor:
Fanny Gallix, Anne-Marie Chevrier, Alexandra Traverse-Glehen, Gilles Salles, Karine Aguera, Yann Godfrin, Willy Berlier
Publikováno v:
Blood. 124:5494-5494
L-asparaginase (L-ASPA) displays a strong clinical benefit in the treatment of acute lymphoblastic leukemia (ALL), where it is included in most of current chemotherapy regimen. L-ASPA depletes plasmatic asparagine (ASN), an amino acid essential for t
Publikováno v:
Cancer Research. 74:5436-5436
Due to asparagine synthetase (ASNS) deficiency, tumors cells auxotrophic for L-asparagine lack capability to synthesize this amino acid and depend to circulating L-asparagine for survival. Based on this rational, L-asparaginase (L-Aspa), an enzyme de
Autor:
Mohamed El Hamri, Yann Godfrin, Xavier Thomas, Marie-Pierre Goutagny, Karine Aguera, Fanny Gallix, Willy Berlier, Yves Bertrand
Publikováno v:
Blood. 122:1423-1423
Introduction The rational of use of L-asparaginase (L-Aspa) is based on asparagine synthetase (ASNS) deficiency in leukemic cells. Its efficacy is due to its capacity to deplete plasmatic asparagine, starving the leukemic cells and subsequently inhib